Go Pro
→ DOJ Admits It In Court—Your Cash Can Be Seized Without Warning (From Priority Gold) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
$8.74
-1.8%		$8.80
$4.50
▼
$10.14
$192.03M2.3275,680 shs20,669 shs
Journey Medical Corporation stock logo
DERM
Journey Medical
$7.30
+1.0%		$7.00
$4.31
▼
$9.56
$206.01M1.09217,286 shs29,516 shs
IBO
Impact Biomedical
$0.48
+3.7%		$0.45
$0.37
▼
$0.83
$51.43M2.761.61 million shs20,356 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$4.07
-2.0%		$4.44
$1.93
▼
$12.46
$194.10M-0.08211,743 shs30,004 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
0.00%-6.51%+0.68%+48.58%-9.18%
Journey Medical Corporation stock logo
DERM
Journey Medical
0.00%-8.02%+7.59%+14.04%+1.69%
IBO
Impact Biomedical
0.00%-14.78%+0.20%-16.63%-35.15%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
0.00%-6.32%-9.39%-5.47%+93.47%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
$8.74
-1.8%		$8.80
$4.50
▼
$10.14
$192.03M2.3275,680 shs20,669 shs
Journey Medical Corporation stock logo
DERM
Journey Medical
$7.30
+1.0%		$7.00
$4.31
▼
$9.56
$206.01M1.09217,286 shs29,516 shs
IBO
Impact Biomedical
$0.48
+3.7%		$0.45
$0.37
▼
$0.83
$51.43M2.761.61 million shs20,356 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$4.07
-2.0%		$4.44
$1.93
▼
$12.46
$194.10M-0.08211,743 shs30,004 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
0.00%-6.51%+0.68%+48.58%-9.18%
Journey Medical Corporation stock logo
DERM
Journey Medical
0.00%-8.02%+7.59%+14.04%+1.69%
IBO
Impact Biomedical
0.00%-14.78%+0.20%-16.63%-35.15%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
0.00%-6.32%-9.39%-5.47%+93.47%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
3.00
Buy$18.00105.97% Upside
Journey Medical Corporation stock logo
DERM
Journey Medical
2.25
Hold$14.0091.78% Upside
IBO
Impact Biomedical
0.00
N/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
1.75
Reduce$10.33153.95% Upside

Current Analyst Ratings Breakdown

Latest IBO, NERV, DERM, and ACOG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$21.00
8/19/2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$21.00
8/17/2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$18.00 ➝ $20.00
8/14/2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$17.00
8/14/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Mixed$7.50 ➝ $10.00
8/13/2026
Journey Medical Corporation stock logo
DERM
Journey Medical
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$12.00 ➝ $15.00
8/12/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/17/2026
Journey Medical Corporation stock logo
DERM
Journey Medical
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/10/2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$20.00
7/10/2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$20.00
6/24/2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
$10.22M18.62N/AN/A$2.88 per share3.03
Journey Medical Corporation stock logo
DERM
Journey Medical
$61.86M3.33N/AN/A$0.96 per share7.60
IBO
Impact Biomedical
$30K1,714.34N/AN/A$0.15 per share3.18
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/A($3.25) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$20.67M-$1.10N/AN/AN/A-153.61%-54.60%-43.47%11/12/2026 (Estimated)
Journey Medical Corporation stock logo
DERM
Journey Medical
-$11.43M-$0.22N/A8.11N/A-8.95%-20.23%-6.60%11/11/2026 (Estimated)
IBO
Impact Biomedical
-$11.84MN/AN/AN/AN/A2,254.28%8.81%4.49%N/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$293.42M-$28.87N/AN/AN/AN/AN/A-31.72%11/4/2026 (Estimated)

Latest IBO, NERV, DERM, and ACOG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
-$0.3921-$0.40-$0.0079-$0.40$4.38 million$6.00 million
8/12/2026Q2 2026
Journey Medical Corporation stock logo
DERM
Journey Medical
-$0.0225-$0.01+$0.0125-$0.01$18.36 million$18.51 million
8/7/2026Q2 2026
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.1933-$0.14+$0.0533-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/AN/AN/AN/AN/A
Journey Medical Corporation stock logo
DERM
Journey Medical
N/AN/AN/AN/AN/A
IBO
Impact Biomedical
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A
9.03
8.04
Journey Medical Corporation stock logo
DERM
Journey Medical
0.64
1.59
1.41
IBO
Impact Biomedical
N/A
0.16
0.13
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
20.15
20.14

Institutional Ownership

CompanyInstitutional Ownership
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A
Journey Medical Corporation stock logo
DERM
Journey Medical
7.25%
IBO
Impact Biomedical
N/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%

Insider Ownership

CompanyInsider Ownership
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
8.60%
Journey Medical Corporation stock logo
DERM
Journey Medical
14.53%
IBO
Impact Biomedical
89.00%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
1.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alpha Cognition Inc. stock logo
ACOG
Alpha Cognition
N/A21.78 million19.91 millionN/A
Journey Medical Corporation stock logo
DERM
Journey Medical
9028.22 million24.12 millionN/A
IBO
Impact Biomedical
N/A107.82 million11.86 millionN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
947.75 million46.94 millionNot Optionable

Recent News About These Companies

Brokerages Set Minerva Neurosciences, Inc (NASDAQ:NERV) Target Price at $10.33
September 13 at 2:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31020116
Minerva Neurosciences, Inc (NASDAQ:NERV) Receives Consensus Recommendation of "Reduce" from Brokerages
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-minerva-neurosciences-inc-nasdaq-nerv-receives-consensus-recommendation-of-reduce-from-brokerages-2026-09-08/
Minerva Neurosciences (NASDAQ:NERV) Stock Crosses Below 200 Day Moving Average - Time to Sell?
September 4, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31002180
Minerva Neurosciences (NASDAQ:NERV) Shares Cross Below 200-Day Moving Average - Here's What Happened
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-minerva-neurosciences-nasdaq-nerv-shares-cross-below-200-day-moving-average-heres-what-happened-2026-09-04/
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
August 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/28/3352656/32445/en/minerva-neurosciences-to-participate-in-two-upcoming-investor-conferences.html
Minerva Neurosciences (NASDAQ:NERV) Share Price Crosses Below 200-Day Moving Average - Here's What Happened
August 22, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/minerva-neurosciences-nasdaqnerv-share-price-crosses-below-200-day-moving-average-heres-what-happened-2026-08-22/
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
August 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/07/3341026/32445/en/minerva-neurosciences-provides-second-quarter-2026-financial-results-and-business-updates.html
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304700/32445/en/minerva-neurosciences-establishes-scientific-advisory-board-to-advance-development-of-roluperidone-and-future-pipeline-programs.html
Minerva Neurosciences Launches ATM Offering to Fund Trial
May 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/minerva-neurosciences-launches-atm-offering-to-fund-trial?utm_source=marketbeat.com&utm_medium=referral
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
May 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2924280/all-you-need-to-know-about-minerva-neurosciences-nerv-rating-upgrade-to-buy?cid=cs-stocknewsapi-ft-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2924280
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
May 20, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2923961/minerva-neurosciences-nerv-loses-37-5-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner?cid=cs-stocknewsapi-ft-tale_of_the_tape|rsi-2923961
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3297009/32445/en/minerva-neurosciences-to-participate-in-the-2026-jefferies-global-healthcare-conference.html
Minerva Neurosciences, Inc: Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
May 5, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68397606-minerva-neurosciences-inc-minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates-399.htm
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287601/32445/en/minerva-neurosciences-provides-first-quarter-2026-financial-results-and-business-updates.html
Minerva Neurosciences (NERV) price target increased by 31.03% to 9.69
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/minerva-neurosciences-nerv-price-target-increased-by-31-03-to-9-69/ar-AA21TjoN
Citizens Initiates Coverage of Minerva Neurosciences (NERV) with Market Outperform Recommendation
April 16, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/citizens-initiates-coverage-of-minerva-neurosciences-nerv-with-market-outperform-recommendation/ar-AA210hf9
Minerva launched with New Outperform at Citizens on schizophrenia candidate
April 15, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4575323-minerva-stock-wins-new-outperform-citizens
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline
April 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/minerva-neurosciences-sets-2026-annual-shareholder-meeting-timeline?utm_source=marketbeat.com&utm_medium=referral
Minerva Announces Leadership Transition
April 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/02/3267830/32445/en/minerva-announces-leadership-transition.html
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3266016/32445/en/minerva-neurosciences-announces-first-patient-screened-in-global-phase-3-confirmatory-trial-of-roluperidone-for-the-treatment-of-negative-symptoms-of-schizophrenia.html
Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia
March 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4887464-minerva-neurosciences-plodding-ahead-after-another-roluperidone-delay

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Shoppers browse folded and hanging clothing in a retail apparel store with shelves and racks displayed.
3 Retail Stocks to Watch After a Big Consumer Earnings Week
By Dan Schmidt | August 29, 2026
Depiction of the banking district in a large city, with an arrow symbolizing bullish momentum.
3 European Banks That Could Win Big From ECB Rate Hikes
By Dan Schmidt | September 14, 2026
Alpha Cognition stock logo

Alpha Cognition NASDAQ:ACOG

$8.74 -0.16 (-1.81%)
As of 11:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Journey Medical stock logo

Journey Medical NASDAQ:DERM

$7.30 +0.07 (+0.97%)
As of 11:36 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

Impact Biomedical NYSEAMERICAN:IBO

$0.48 +0.02 (+3.65%)
As of 11:36 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Impact Biomedical, Inc. (“IBIO”) currently is a holding company operating mainly through our majority owned subsidiary, Global BioLife, Inc., which was incorporated on April 14, 2017. The Company is committed to both funding research and developing intellectual property portfolio. We currently focus on research in three main areas: (i) development of a universal therapeutic drug platform; (ii) a new sugar substitute; and (iii) a multi-use fragrance. IBIO discovers, confirms, and patents unique science and technologies which can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships. Currently, our operations are conducted, and our assets are owned through our principal subsidiaries: (i) Global BioLife, Inc. (“Global BioLife”), which was incorporated on April 14, 2017, (ii) Impact BioLife Science (“Impact BioLife”), which was incorporated on August 28, 2020, (iii) Global BioMedical, Inc. (“Global BioMedical”), which was incorporated on April 18, 2017, and (iv) Sweet Sense, Inc. (“Sweet Sense”), which was incorporated on April 30, 2018. By leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals and over the counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological, oncology and immuno-related diseases. In addition to our existing efforts, we continually search for and evaluate other potential new offerings to add to our portfolio. Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors and development partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBIO technologies in exchange for milestone, and royalty licensing payments. Below is a list of our principal subsidiaries: . Impact BioLife Science, Inc.; . Global Biomedical, Inc.; . Global BioLife, Inc.; and . Sweet Sense, Inc. Impact BioLife Science, Inc. We are the sole owner of the outstanding equity of Impact BioLife Science, Inc. Global Biomedical, Inc. We own 90.9% of Global Biomedical, Inc.’s outstanding equity. Global BioLife, Inc. Through our majority owned subsidiary Global Biomedical, Inc., we own 81.8% of the outstanding equity of Global BioLife, Inc. Sweet Sense, Inc. We are the owner of 95.5% of the outstanding equity of Sweet Sense. Impact BioMedical Inc. is a Nevada corporation and was incorporated in October 2018. Our principal executive offices are located at 1400 Broadfield Blvd., Suite 130, Houston, Texas.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$4.07 -0.08 (-1.95%)
As of 11:36 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas